Analysts Set Korro Bio, Inc. (NASDAQ:KRRO) Target Price at $144.00

Korro Bio, Inc. (NASDAQ:KRRO) has received a consensus recommendation of “Buy” from the seven analysts that are presently covering the stock, Marketbeat reports. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $144.00.

Several research firms have weighed in on KRRO. Raymond James began coverage on shares of Korro Bio in a report on Monday, October 21st. They set a “strong-buy” rating and a $153.00 target price for the company. Oppenheimer began coverage on shares of Korro Bio in a report on Friday, January 10th. They set an “outperform” rating and a $155.00 price target for the company. Royal Bank of Canada lifted their price target on shares of Korro Bio from $95.00 to $105.00 and gave the stock an “outperform” rating in a report on Monday, October 21st. William Blair reiterated an “outperform” rating on shares of Korro Bio in a report on Wednesday, November 13th. Finally, HC Wainwright reiterated a “buy” rating and set a $115.00 price target on shares of Korro Bio in a report on Friday, November 22nd.

Korro Bio Trading Down 0.2 %

Shares of NASDAQ KRRO opened at $34.12 on Wednesday. The firm has a 50-day moving average price of $42.00 and a 200 day moving average price of $45.64. Korro Bio has a 52 week low of $30.00 and a 52 week high of $98.00.

Korro Bio (NASDAQ:KRRO) last posted its earnings results on Tuesday, November 12th. The company reported ($2.26) earnings per share for the quarter, beating the consensus estimate of ($2.55) by $0.29. Analysts anticipate that Korro Bio will post -9.52 EPS for the current fiscal year.

Insider Buying and Selling at Korro Bio

In related news, CFO Vineet Agarwal sold 800 shares of the company’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $70.00, for a total value of $56,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 5.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Korro Bio

Institutional investors have recently added to or reduced their stakes in the business. Quest Partners LLC grew its position in shares of Korro Bio by 172.1% during the third quarter. Quest Partners LLC now owns 1,777 shares of the company’s stock worth $59,000 after acquiring an additional 1,124 shares during the last quarter. Brown Brothers Harriman & Co. lifted its holdings in Korro Bio by 251.0% in the third quarter. Brown Brothers Harriman & Co. now owns 2,854 shares of the company’s stock worth $95,000 after purchasing an additional 2,041 shares during the period. Vestcor Inc acquired a new stake in Korro Bio in the third quarter worth about $100,000. MetLife Investment Management LLC lifted its holdings in Korro Bio by 129.0% in the third quarter. MetLife Investment Management LLC now owns 3,639 shares of the company’s stock worth $122,000 after purchasing an additional 2,050 shares during the period. Finally, BNP Paribas Financial Markets lifted its holdings in Korro Bio by 1,018.2% in the third quarter. BNP Paribas Financial Markets now owns 4,909 shares of the company’s stock worth $164,000 after purchasing an additional 4,470 shares during the period. Institutional investors own 13.18% of the company’s stock.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).